Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
As the AIDS epidemic continues unabated, the development of a human immunodeficiency virus (HIV) vaccine is critical. Ideally, an effective vaccine should elicit cell-mediated and neutralizing humoral immune responses. We have determined the in vitro susceptibility profile of sexually transmitted viruses from 91 patients with acute and early HIV-1 infection to three monoclonal antibodies, 2G12, 2F5, and 4E10. Using a recombinant virus assay to measure neutralization, we found all transmitted viruses were neutralized by 4E10, 80% were neutralized by 2F5, and only 37% were neutralized by 2G12. We propose that the induction of 4E10-like antibodies should be a priority in designing immunogens to prevent HIV-1 infection.
Mehandru
Saurabh
S
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave., 7th Floor, New York, NY 10016, USA.
Wrin
Terri
T
Galovich
Justin
J
Stiegler
Gabriela
G
Vcelar
Brigitta
B
Hurley
Arlene
A
Hogan
Christine
C
Vasan
Sandhya
S
Katinger
Hermann
H
Petropoulos
Christos J
CJ
Markowitz
Martin
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D015483:HIV Antibodies / Q000008:administration & dosage / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008297:Male; D009500:Neutralization Tests; D011995:Recombination, Genetic; D012725:Sexual Behavior
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies